BioSpace News Archive

The two companies said a booster dose given six months after the second dose had a consistent tolerability profile while still creating high immune responses against the Alpha and Beta variant.

Sparx Therapeutics is expanding its operations into Yangzhou, China, with the imminent construction of a 1.2 million square foot facility for its commercial production.

Haemonetics Corporation announced that the Company intends to publish first quarter fiscal year 2022 financial results at 6:00 am EDT on Wednesday, August 11, 2021.

via NewMediaWire – Nephros, Inc., a leading water technology company providing filtration and pathogen detection solutions to the medical and commercial markets, has been invited to present at the Access to Giving Virtual Investor conference, which is being held July 13-15.

Jaguar Health, Inc. announced that it has adjourned its Annual Meeting of Stockholders held on May 13, 2021 for a third time due to a lack of quorum.

Sensient Technologies Corporation will hold its conference call to discuss 2021 second quarter results at 8:30 a.m. CDT on Friday, July 23, 2021.

Ocuphire Pharma, Inc., announced that the Compensation Committee of its Board of Directors, which is composed entirely of independent directors, approved an equity award under Ocuphire’s Inducement Plan, as a material inducement to Amanda Providakes in connection with her employment with the Company effective on July 6, 2021.

PharmaCyte Biotech, Inc., a biotechnology company focused on developing cellular therapies for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, announced that it will effect a 1-for-1,500 reverse stock split of its shares of common stock, leaving the Company with only about 1.6 million issued and outstanding shares.

Celldex Therapeutics, Inc. announced updated data from the Company’s ongoing, open label Phase 1b clinical trial of CDX-0159 in patients with antihistamine refractory cold urticaria and symptomatic dermographism, the two most common forms of chronic inducible urticaria.

The ultrasound transducer market is expected to reach US$ 5,020.76 million in 2027 from US$ 3,816.25 million in 2019; it is estimated to grow at a CAGR of 3.6% from 2020-2027.